NEO-EXCEL Trial In 'NEO-EXCEL trial' NEO-EXCEL TrialFor trial participantsFor investigatorsContact us Phase III neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal early breast cancer. EudraCT number 2006-000436-27 Study number BR3031 Status Closed Opened August 2007 Expected recruitment duration 7 Years A randomised, phase III, bifactorial clinical trial for ER positive postmenopausal early breast cancer to determine whether the addition of a COX 2 inhibitor to a 16 week treatment regimen of pre-operative exemestane or letrozole results in greater clinical response, with acceptable toxicity, than an aromatase inhibitor alone; and to determine whether exemestane provides greater objective clinical response than letrozole in the neoadjuvant setting. For general enquires about the trial please email neoexcel@trials.bham.ac.uk. NEO-EXCEL is an NCRN adopted trial. Trial Documents A link to the current trial protocol is provided below. If there has been a recent amendment to the trial please ensure you have R&D approval for this specific version of the protocol before using as a reference. Trial Protocol v9.0 [.pdf] More Information The NEO-EXCEL trial results can be found on the Cancer Research UK website.